Stanley Laman Group, Ltd. Celyad Oncology Sa Transaction History

Stanley Laman Group, Ltd.

  • $652 Million
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 07, 2019
SELL
$16.0 - $28.17 $636,000 - $1.12 Million
-39,750 Closed
0 $0
Q3 2018

Oct 30, 2018
BUY
$26.49 - $31.86 $32,450 - $39,028
1,225 Added 3.18%
39,750 $1.05 Million
Q2 2018

Aug 09, 2018
BUY
$26.05 - $35.15 $1 Million - $1.35 Million
38,525 New
38,525 $1.15 Million

About Celyad Oncology SA

CYAD Quotes by TradingView
  • Ticker CYAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,594,000
  • Market Cap $11.7M
  • Description
  • Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cance...
More about CYAD
Track This Portfolio

Track Stanley Laman Group, Ltd. Portfolio

Follow Stanley Laman Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stanley Laman Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Stanley Laman Group, Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email